Notizie e Video - ICO THERAPEUTICS ICOTF - Pagina 5

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial 30.05.2018 / 22:19 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are...

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). 201 7 Financial & Operational Highlights During the year, we advanced our oral formulation of Amphotericin B completing our 14-day GLP toxicology...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Year End 2017 Financial Results 25.04.2018 / 02:47 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and...

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B. "Dosing our first patient is a major milestone for iCo Therapeutics and the oral Amphotericin B program" stated Andrew Rae, President and CEO of iCo Therapeutics Inc. "We currently remain on track...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Major Milestone - Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study 18.04.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has...

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). "During the quarter, we continued to advance our novel Oral Amphotericin B (Oral Amp B) candidate towards the clinic, and we are pleased that...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study 22.11.2017 / 19:20 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), and its recently formed subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has been...

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its recently formed subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has been granted ethics approval in Australia to conduct its proposed Phase 1 clinical study for Oral Amphotericin B. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections but the therapy is currently limited by...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Upcoming Presentations and Meetings 08.09.2017 / 01:11 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - September 7, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today announced that it has been invited to present at the following upcoming conferences: 19 th Annual Rodman and Renshaw Global Investment...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Second Quarter 2017 Financial Results 29.08.2017 / 23:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - August 29, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported financial results for the quarter ended June 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset 15.06.2017 / 22:15 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Positive Oral Amphotericin Study 12.06.2017 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from...

VANCOUVER, BC / ACCESSWIRE / April 19, 2017 / iCo Therapeutics (TSX-V: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). 201 6 Financial & Operational Highlights We continued to advance our Oral Amphotericin B Delivery System (Oral Amp B), undertaking pre-clinical pharmacokinetic and...

VANCOUVER, BC / ACCESSWIRE / March 13, 2017 / iCo Therapeutics Inc. (TSX-V: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") reports that, at the request of IIROC, the Company wishes to confirm that management is unaware of any material change in their operations that would account for the recent increase in market activity. About iCo Therapeutics iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Provides Multiple Corporate Updates 23.01.2017 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - January 23, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company') announces several corporate developments. Regarding our Oral Amphotericin B program, multiple, additional pre-clinical studies have been initiated including a...

VANCOUVER, BC / ACCESSWIRE / January 23, 2017 / iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces several corporate developments. Regarding our Oral Amphotericin B program, multiple, additional pre-clinical studies have been initiated including a multi-day fasted/fed study, a 7-day dose range finding study and, importantly, a 14 day GLP toxicology study. iCo expects all three studies to be substantially complete during Q1 2017. Together these studies will be...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous CLARIFICATION: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program 28.11.2016 / 17:53 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ('iCo' or 'the Company'), announces several developments related to its novel, patent protected formulation...

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program 28.11.2016 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ('iCo' or 'the Company') announces several developments related to its novel, patent protected formulation of generic...

VANCOUVER, BC / ACCESSWIRE / November 28, 2016 / iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company"), announces several developments related to its novel, patent protected formulation of generic Amphotericin B: Positive Oral Amphotericin B (Oral Amp B) study results exhibited pharmacokinetic (PK) and tissue accumulation data with clinical and commercial relevance: demonstrating scalable and stable drug product, now at a higher dose form once daily regime may be possible for our...

VANCOUVER, BC / ACCESSWIRE / November 28, 2016 / iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") announces several developments related to its novel, patent protected formulation of generic Amphotericin B: - Positive Oral Amphotericin B (Oral Amp B) study results exhibited pharmacokinetic (PK) and tissue accumulation data with clinical and commercial relevance: demonstrating scalable and stable drug product, now at a higher dose form once daily regime may be possible for our...